121 related articles for article (PubMed ID: 1542094)
1. 4-substituted 2-alkoxytetrahydrofurans as potent and long-lasting PAF antagonists.
Carceller E; Merlos M; Giral M; Bartrolí J; García-Rafanell J; Forn J
J Med Chem; 1992 Feb; 35(4):676-83. PubMed ID: 1542094
[TBL] [Abstract][Full Text] [Related]
2. Disubstituted tetrahydrofurans and dioxolanes and PAF antagonists.
Bartrolí J; Carceller E; Merlos M; García-Rafanell J; Forn J
J Med Chem; 1991 Jan; 34(1):373-86. PubMed ID: 1992139
[TBL] [Abstract][Full Text] [Related]
3. Platelet activating factor antagonists: synthesis and structure-activity studies of novel PAF analogues modified in the phosphorylcholine moiety.
Takatani M; Yoshioka Y; Tasaka A; Terashita Z; Imura Y; Nishikawa K; Tsushima S
J Med Chem; 1989 Jan; 32(1):56-64. PubMed ID: 2909744
[TBL] [Abstract][Full Text] [Related]
4. Beneficial effects of TCV-309, a novel potent and selective platelet activating factor antagonist in endotoxin and anaphylactic shock in rodents.
Terashita Z; Kawamura M; Takatani M; Tsushima S; Imura Y; Nishikawa K
J Pharmacol Exp Ther; 1992 Feb; 260(2):748-55. PubMed ID: 1738121
[TBL] [Abstract][Full Text] [Related]
5. Design, synthesis, and structure-activity relationship studies of novel 1-[(1-acyl-4-piperidyl)methyl]-1H-2- methylimidazo[4,5-c]pyridine derivatives as potent, orally active platelet-activating factor antagonists.
Carceller E; Merlos M; Giral M; Balsa D; García-Rafanell J; Forn J
J Med Chem; 1996 Jan; 39(2):487-93. PubMed ID: 8558517
[TBL] [Abstract][Full Text] [Related]
6. CV-6209, a highly potent antagonist of platelet activating factor in vitro and in vivo.
Terashita Z; Imura Y; Takatani M; Tsushima S; Nishikawa K
J Pharmacol Exp Ther; 1987 Jul; 242(1):263-8. PubMed ID: 3612533
[TBL] [Abstract][Full Text] [Related]
7. Inhibitory effects of the novel platelet activating factor receptor antagonist, 1-ethyl-2-[N-(2-methoxy)benzoyl-N-[(2R)-2-methoxy-3-(4- octadecylcarbamoyloxy) piperidinocarbonyloxypropyloxy]carbonyl] aminomethyl-pyridinium chloride, in several experimentally induced shock models.
Nagaoka J; Harada K; Kimura A; Kobayashi S; Murakami M; Yoshimura T; Yamada K; Asano O; Katayama K; Yamatsu I
Arzneimittelforschung; 1991 Jul; 41(7):719-24. PubMed ID: 1663352
[TBL] [Abstract][Full Text] [Related]
8. Platelet-activating factor (PAF) antagonistic actions of two new analogs of tetrahydrofurans.
Tsao PS; Stahl GA; Lefer AM; Salvino J; Pietranico S; Nicolaou KC
J Lipid Mediat; 1989; 1(3):189-99. PubMed ID: 2519893
[TBL] [Abstract][Full Text] [Related]
9. [(3-Pyridylalkyl)piperidylidene]benzocycloheptapyridine derivatives as dual antagonists of PAF and histamine.
Carceller E; Merlos M; Giral M; Balsa D; Almansa C; Bartrolí J; García-Rafanell J; Forn J
J Med Chem; 1994 Aug; 37(17):2697-703. PubMed ID: 7914928
[TBL] [Abstract][Full Text] [Related]
10. 1,4-Dihydropyridines as antagonists of platelet activating factor. 1. Synthesis and structure-activity relationships of 2-(4-heterocyclyl)phenyl derivatives.
Cooper K; Fray MJ; Parry MJ; Richardson K; Steele J
J Med Chem; 1992 Aug; 35(17):3115-29. PubMed ID: 1507200
[TBL] [Abstract][Full Text] [Related]
11. Analogues of platelet activating factor. 8. Antagonists of PAF containing an aromatic ring linked to a pyridinium ring.
Trova MP; Wissner A; Carroll ML; Kerwar SS; Pickett WC; Schaub RE; Torley LW; Kohler CA
J Med Chem; 1993 Mar; 36(5):580-90. PubMed ID: 8496938
[TBL] [Abstract][Full Text] [Related]
12. Derivatives of 2-methylenepropane-1,3-diol as new antagonists of platelet activating factor.
Grue-Sørensen G; Nielsen IM; Nielsen CK
J Med Chem; 1988 Jun; 31(6):1174-8. PubMed ID: 3373485
[TBL] [Abstract][Full Text] [Related]
13. Structure-activity relationships in platelet-activating factor (PAF antagonists). 6. Synthesis and in vitro antagonistic activities of 2-substituted 5-oxotetrahydrofurans.
Favre E; Heymans F; Redeuilh C; Batt JP; Massicot F; Blavet N; Braquet P; Godfroid JJ
J Lipid Mediat; 1992 Feb; 5(1):23-40. PubMed ID: 1449553
[TBL] [Abstract][Full Text] [Related]
14. Pharmacologic activity of bepafant (WEB 2170), a new and selective hetrazepinoic antagonist of platelet activating factor.
Heuer HO; Casals-Stenzel J; Muacevic G; Weber KH
J Pharmacol Exp Ther; 1990 Dec; 255(3):962-8. PubMed ID: 2262914
[TBL] [Abstract][Full Text] [Related]
15. 4-Alkyl-1,4-dihydropyridines derivatives as specific PAF-acether antagonists.
Sunkel CE; de Casa-Juana MF; Santos L; Gómez MM; Villarroya M; González-Morales MA; Priego JG; Ortega MP
J Med Chem; 1990 Dec; 33(12):3205-10. PubMed ID: 2175357
[TBL] [Abstract][Full Text] [Related]
16. Pharmacological profile of epiyangambin: a furofuran lignan with PAF antagonist activity.
Castro-Faria-Neto HC; Martins MA; Silva PM; Bozza PT; Cruz HN; de Queiroz-Paulo M; Kaplan MA; Cordeiro RS
J Lipid Mediat; 1993 May; 7(1):1-9. PubMed ID: 8358020
[TBL] [Abstract][Full Text] [Related]
17. Pharmacological profile of TCV-309--a potent PAF antagonist.
Terashita Z; Takatani M; Nishikawa K
J Lipid Mediat; 1992; 5(2):183-5. PubMed ID: 1445598
[TBL] [Abstract][Full Text] [Related]
18. A novel class of platelet activating factor (PAF) antagonists. II. Modification of the 2-position of the glycerol backbone of PAF-sulfonamide isosteres.
Tsuri T; Matsui T; Haga N; Kamata S; Hagishita S; Takahashi K; Kakushi H; Uchida K; Hatakeyama H; Kurosawa A
Chem Pharm Bull (Tokyo); 1992 Jan; 40(1):85-95. PubMed ID: 1576692
[TBL] [Abstract][Full Text] [Related]
19. Involvement of nitric oxide and eicosanoids in platelet-activating factor-induced haemodynamic and haematological effects in dogs.
Noguchi K; Matsuzaki T; Shiroma N; Ojiri Y; Sakanashi M
Br J Pharmacol; 1996 Jun; 118(4):941-50. PubMed ID: 8799566
[TBL] [Abstract][Full Text] [Related]
20. Development, synthesis, and biological evaluation of (-)-trans-(2S,5S)-2-[3-[(2-oxopropyl)sulfonyl]-4-n-propoxy-5-(3- hydroxypropoxy)-phenyl]-5-(3,4,5-trimethoxyphenyl)tetrahydrofuran, a potent orally active platelet-activating factor (PAF) antagonist and its water-soluble prodrug phosphate ester.
Girotra NN; Biftu T; Ponpipom MM; Acton JJ; Alberts AW; Bach TN; Ball RG; Bugianesi RL; Parsons WH; Chabala JC
J Med Chem; 1992 Sep; 35(19):3474-82. PubMed ID: 1404229
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
